497. Identification of Patients at Risk of Clostridium difficile Infection for Enrollment in Vaccine Clinical Trials
Session: Poster Abstract Session: Healthcare Epidemiology: Updates in C. difficile
Thursday, October 4, 2018
Room: S Poster Hall
Background:

Vaccine efficacy trials against C. difficile infection (CDI) require a study population with an observed event rate that supports feasibility and timely study completion. The goal of this study was to develop a predictive algorithm to identify patients at high risk of developing CDI over the next 2-12 months for enrollment in a vaccine clinical trial.

Methods:

We conducted a two-stage retrospective study of patients within the US Department of Veterans Affairs Health system between January 1, 2009 and December 31, 2013. Included patients were age 50 years or older, had at least 1 visit in each of the 2 years (2007 and 2008) prior to the study and had no CDI in the 12 months prior to and the first month of the study. In stage 1 we used a case-cohort design to identify factors (patient-month level) for predicting the risk of CDI in months 2-12. The stage 1 algorithm was then applied to the VA population and a calculated risk score generated at each patient visit (inpatient or outpatient). Patients were included in the stage 2 cohort at the first time their stage 1 risk score crossed the designated risk threshold. The stage 2 algorithm incorporated additional factors including medications and laboratory variables. Multivariable logistic regression with elastic net regularization was used to select final predictors in both stage 1 and stage 2 algorithms. The final algorithm consisted of sequential application of predictive algorithms in stage 1 and 2. Performance was measured using the positive predictive value (PPV) and the area under the curve (AUC).

Results:

Risk factors in the final algorithm included baseline comorbidity score, acute renal failure, sepsis, UTI or pneumonia in the current month, UTI in the previous month, having an albumin or hematocrit test performed, high risk antibiotics in the previous 3 months, hemodialysis in the last month, race, and the number and duration of acute and long-term care visits in the last month. The final algorithm resulted in an AUC of 0.69 and a PPV of 3.4%, largely enriching for the risk of CDI in months 2-12.

Conclusion:

We developed a predictive algorithm to identify a patient population with increased risk of CDI over the next 2-12 months. Predictive models have the potential to improve enrollment and feasibility of clinical trials.

Vanessa Stevens, PhD1,2, Ellyn Russo, MS3, Yinong Young-Xu, ScD, MS, MA3,4, Molly Leecaster, PhD1,2, Yue Zhang, PhD2, Chong Zhang, MS2, Holly Yu, MSPH5, Bing Cai, PhD6, Elisa Gonzalez, MSc7, Dale N Gerding, MD, FIDSA8, Jody Lawrence, MD6 and Matthew Samore, MD, FSHEA9, (1)Ideas Center of Innovation, VA Salt Lake City Health Care System, Salt Lake City, UT, (2)Internal Medicine, University of Utah, Salt Lake City, UT, (3)Clinical Epidemiology Program, Veterans Affairs Medical Center, White River Junction, VT, (4)Department of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, NH, (5)Pfizer, Inc., Collegeville, PA, (6)VRD Clinical Research & Development, Pfizer, Inc., Collegeville, PA, (7)Health Economics and Outcomes Research, Pfizer, Inc., Collegeville, PA, (8)Loyola University, Hines, IL, (9)University of Utah School of Medicine, Division of Epidemiology, Salt Lake City, UT

Disclosures:

V. Stevens, Pfizer, Inc.: Grant Investigator , Research grant .

E. Russo, Pfizer, Inc.: Grant Investigator , Research grant .

Y. Young-Xu, Pfizer, Inc.: Grant Investigator , Research grant .

M. Leecaster, None

Y. Zhang, Pfizer, Inc.: Investigator , Research grant .

C. Zhang, Pfizer, Inc.: Investigator , Research grant .

H. Yu, Pfizer, Inc: Employee and Shareholder , Salary .

B. Cai, Pfizer, Inc.: Employee , Salary .

E. Gonzalez, Pfizer, Inc.: Employee , Salary .

D. N. Gerding, Merck: Scientific Advisor , Consulting fee . Actelion: Scientific Advisor , Consulting fee . DaVolterra: Scientific Advisor , Consulting fee . Summit: Scientific Advisor , Consulting fee . Rebiotix: Medical Officer and Scientific Advisor , Consulting fee . Pfizer: Consultant , Consulting fee . MGB Pharma: Consultant , Consulting fee . Sanofi Pasteur: Consultant , Consulting fee . Seres: Investigator , Research grant . CDC: Investigator , Research grant . US Dept VA: Investigator , Research grant . Treatment/Prevention of C. difficile: Patent Holder , no license or royalties .

J. Lawrence, Pfizer, Inc.: Employee , Salary .

M. Samore, Pfizer, Inc.: Grant Investigator , Research grant .

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.